Landscape of CCA/Ph⁻ in patients with chronic-phase chronic myeloid leukemia. (A) Distribution of CCA/Ph⁻ according to the year after treatment start it is first detected. (B) Number of times CCA/Ph⁻ is detected in independent cytogenetic analyses per patient, done every 3 months during the first year, then every 6 to 12 months while on study. (C) Maximum number of metaphases containing CCA/Ph⁻ in a cytogenetic analysis per patient. (D) Distribution of CCA/Ph⁻ by chromosome. Each row represents the chromosomes numbered from 1 to 22 with additional rows for the sex chromosomes and a row labeled “C” for patients with a complex karyotype defined as ≥3 chromosomal abnormalities in 1 metaphase. Each column represents a patient with CCA/Ph⁻. Red. deletion or loss; blue. gain; D, dasatinib; I, imatinib; N, nilotinib; P, ponatinib. Some of the CCA/Ph⁻ metaphases were translocations not shown in this figure. Additional details are provided in supplemental Table 1.